February 28, 2015 11:24 AM ET

Biotechnology

Company Overview of Tamir Biotechnology, Inc.

Company Overview

Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...

12625 High Bluff Drive

Suite 113

San Diego, CA 92130

United States

Founded in 1981

Phone:

732-823-1003

Fax:

732-230-3794

Key Executives for Tamir Biotechnology, Inc.

Chief Executive Officer, President, Secretary, and Director
Age: 48
Chief Financial Officer and Secretary
Age: 52
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Age: 73
Compensation as of Fiscal Year 2014.

Tamir Biotechnology, Inc. Key Developments

Tamir Biotechnology, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014

Tamir Biotechnology, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014 . Venue: Westin San Francisco Market Street, San Francisco, California, United States.

SEC Revokes Registration Of Registered Securities Of Tamir Biotechnology

An Administrative Law Judge has issued an Initial Decision as to Tamir Biotechnology, Inc. (Tamir), in Medis Technologies Ltd., Admin. Proc. File No. 3-15185. The Order Instituting Proceedings alleged that Tamir repeatedly failed to file required annual and quarterly reports while its securities were registered with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of the registered securities of Tamir, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (Exchange Act).

Tamir Biotechnology, Inc. Announces Auditor Changes

On March 25, 2013, following the recommendation of its Audit Committee, Tamir Biotechnology, Inc., dismissed CohnReznick LLP as the Company’s independent registered public accounting firm. On March 25, 2013, following the recommendation of its Audit Committee, the Company engaged Goldman Kurland and Mohidin, LLP, as its independent accountants to audit the Company's financial statements for its fiscal years ended July 31, 2011, 2012 and 2013.

Similar Private Companies By Industry

Company Name Region
D-finitive Technologies, Inc. United States
Dark Horse Consulting Inc. United States
Capricorn Products, LLC United States
Qwell Pharmaceuticals, Inc. United States
Ensemble Therapeutics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 25, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tamir Biotechnology, Inc., please visit www.alfacell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.